Executive Summary
Cannabis Suisse Corp (CSUI) reported QQ1 2025 revenue of $7,500 with a modest gross profit of $144, translating to a gross margin of 1.92%. The quarter delivered a substantial operating loss of $74,839 and a net loss of $535,086, resulting in an EPS of −0.0076 for the period. EBITDA deteriorated to $(519,176) with an EBITDAR of $(69.22)%, underscoring that the company’s cost structure far outpaced top-line revenue once financing and non-cash items are accounted for. Despite a flat revenue base versus the prior year (YoY revenue change 0.0%), the gross profit declined sharply year-over-year by approximately 77%, while QoQ gross profit improved meaningfully by about 107% from the prior quarter, reflecting a volatile margin engine and potential one-off cost dynamics.
Key Performance Indicators
QoQ: 107.42% | YoY:-77.00%
QoQ: 50.32% | YoY:-726.30%
QoQ: 66.67% | YoY:-406.67%
Key Insights
Revenue: $7,500 in QQ1 2025 (YoY 0.00%; QoQ 0.00%). Gross Profit: $144; Gross Margin 1.92% (YoY -77.0%, QoQ +107.4%). Operating Income: $(74,839); Operating Margin −9.98% (YoY −23.46%, QoQ +9.57%). Net Income: $(535,086); Net Margin −71.34% (YoY −726.30%, QoQ +50.32%). EBITDA: $(519,176); EBITDA Margin −69.22%. EPS: $(0.0076); EPS YoY −406.67%, QoQ +66.67%. Interest Expense: $14,849. Depreciation/Amortization: shown as negative $(444,337) which appears anomalous and warrants clarific...
Financial Highlights
Revenue: $7,500 in QQ1 2025 (YoY 0.00%; QoQ 0.00%). Gross Profit: $144; Gross Margin 1.92% (YoY -77.0%, QoQ +107.4%). Operating Income: $(74,839); Operating Margin −9.98% (YoY −23.46%, QoQ +9.57%). Net Income: $(535,086); Net Margin −71.34% (YoY −726.30%, QoQ +50.32%). EBITDA: $(519,176); EBITDA Margin −69.22%. EPS: $(0.0076); EPS YoY −406.67%, QoQ +66.67%. Interest Expense: $14,849. Depreciation/Amortization: shown as negative $(444,337) which appears anomalous and warrants clarification. Net cash from operating activities: $(5,320). Free Cash Flow: $(5,320). Cash at end of period: $25,742. Total assets: $833,847. Total liabilities: $2,714,763. Total stockholders’ equity: $(1,880,916) (negative). Current ratio: 0.738; Quick ratio: 0.738; Cash ratio: 0.109. Long-term debt: $2,477,969; Total debt: $2,686,311. Equity multiplier: negative, reflecting negative shareholders’ equity. Price-to-sales: 235.60; Enterprise value multiple: −8.53.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
7.50K |
0.00% |
0.00% |
| Gross Profit |
144.00 |
-77.00% |
107.42% |
| Operating Income |
-74.84K |
-23.46% |
9.57% |
| Net Income |
-535.09K |
-726.30% |
50.32% |
| EPS |
-0.01 |
-406.67% |
66.67% |
Key Financial Ratios
operatingProfitMargin
-998%
operatingCashFlowPerShare
$-0
Management Commentary
No earnings call transcript was provided in the dataset. Consequently, there are no management quotes or sectioned highlights to extract for themes such as strategy, operations, or market conditions. If a transcript is supplied, a subsequent pass can append thematically grouped highlights with context and significance.
Forward Guidance
Management guidance is not embedded in the provided data. Given the QQ1 2025 results, the near-term outlook hinges on meaningful top-line progression or substantial cost rationalization. Absent a capital infusion or debt restructuring, the company faces liquidity risk and balance-sheet stress. Investors should monitor: (1) any announced debt restructurings or equity financings, (2) updates on product mix, regulatory status, and commercialization of CBD/OTC offerings, (3) changes in working capital and cash burn trajectory, and (4) potential asset impairments or strategic alternatives (e.g., divestitures, partnerships, or portfolio optimization).